1. Barreiro TJ, Perillo I. An approach to interpreting spirometry. Am Fam Physician. 2004; 69(5):1107–1114.
2. Villegas R, Xiang YB, Cai Q, Fazio S, Linton M, Li H, et al. Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab Syndr Relat Disord. 2010; 8(3):263–270.
3. Nicks ME, O'Brien MM, Bowler RP. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. COPD. 2011; 8(4):264–269.
4. Durmus Kocak N, Sasak G, Aka Akturk U, Akgun M, Boga S, Sengul A, et al. Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease. Med Sci Monit. 2016; 22:4169–4176.
5. Aida Y, Shibata Y, Osaka D, Abe S, Inoue S, Fukuzaki K, et al. The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci. 2011; 8(6):470–478.
6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26(2):186–191.
7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765–773.
8. B L, T W, Hn Z, Ww Y, Hp Y, Cx L, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health. 2011; 11:832.
9. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018; 37(9):2529–2538.
10. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005; 127(2):558–564.
11. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, Johnson LR, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med. 1995; 151(6):1778–1785.
12. Shibata Y, Inoue S, Watanabe M. Impact of reduced pulmonary function in the Japanese general population: lessons from the Yamagata-Takahata study. Respir Investig. 2019; 57(3):220–226.
13. Fukuhara A, Saito J, Sato S, Saito K, Fukuhara N, Tanino Y, et al. The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. Int J Chron Obstruct Pulmon Dis. 2017; 12:1213–1219.
14. Koran Centers for Disease Control and Prevention (KCDC). Korea National Health and Nutrition Examination Survey (KNHANES) [Internet]. Cheongju: KCDC;2018. Accessed Jul 27, 2018. Available from:
https://knhanes.cdc.go.kr/knhanes/main.do.
15. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995; 152(3):1107–1136.
16. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis. 2005; 58(3):230–242.
17. Sarangi R, Varadhan N, Bahinipati J, Dhinakaran A, Anandaraj , Ravichandran K. Serum uric acid in chronic obstructive pulmonary disease: a hospital based case control study. J Clin Diagn Res. 2017; 11(9):BC09–BC13.
18. Song JU, Hwang J, Ahn JK. Serum uric acid is positively associated with pulmonary function in Korean health screening examinees. Mod Rheumatol. 2017; 27(6):1057–1065.
19. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63(10):3136–3141.
20. Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol. 2005; 147:132–148.
21. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(2):170–180.
22. Kim JW, Kwak SG, Lee H, Kim SK, Choe JY, Park SH. Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015. Rheumatol Int. 2017; 37(9):1499–1506.
23. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005; 69(8):928–933.
24. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003; 16(6):429–433.
25. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59(7):574–580.
26. Garcia-Pachon E, Padilla-Navas I, Shum C. Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. Lung. 2007; 185(1):21–24.
27. Zhang X, Liu L, Liang R, Jin S. Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015; 10:2519–2523.
28. Bartziokas K, Papaioannou AI, Loukides S, Papadopoulos A, Haniotou A, Papiris S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J. 2014; 43(1):43–53.